H.C. Wainwright Reaffirms Their Buy Rating on Spectrum Pharmaceuticals (SPPI)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Spectrum Pharmaceuticals (SPPIResearch Report), with a price target of $4.00. The company’s shares opened today at $0.40.

According to TipRanks, White is an analyst with an average return of -21.8% and a 26.45% success rate. White covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Spectrum Pharmaceuticals, and G1 Therapeutics.

In addition to H.C. Wainwright, Spectrum Pharmaceuticals also received a Buy from JMP Securities’s Reni Benjamin in a report issued on November 21. However, on November 16, B.Riley Financial downgraded Spectrum Pharmaceuticals (NASDAQ: SPPI) to a Hold.

See today’s best-performing stocks on TipRanks >>

SPPI market cap is currently $87.32M and has a P/E ratio of -0.68.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.

Read More on SPPI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More